Cardiff Oncology, Inc. (CRDF) 2017年年度报告「NASDAQ」.pdf

《Cardiff Oncology, Inc. (CRDF) 2017年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Cardiff Oncology, Inc. (CRDF) 2017年年度报告「NASDAQ」.pdf（101页珍藏版）》请在三个皮匠报告上搜索。

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549Form 10-K(Mark One)xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2017oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934

2、For the Transition Period from to Commission File Number:001-35558TROVAGENE,INC.(Exact name of registrant as specified in its charter)Delaware 27-2004382(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)11055 Flintkote Avenue,Suite B,San Diego,Californi

3、a 92121(Address of principal executive offices)(Zip Code)(858)952-7570(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each class Name of each exchange on which registeredCommon Stock,$0.0001 par value The NASDAQ Capital MarketSecur

4、ities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes o No xIndicate by check if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the A

5、ct.Yes o No xIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject

6、to such filingrequirements for the past 90 days.Yes x No oIndicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site,if any,every Interactive Data Filerequired to be submitted and posted pursuant to Rule 405 of Regulation S-T(232.405 of this chapt